SCHEMBL3889424

SCHEMBL3889424

CCOC(=O)C[C@@H](c1ccc2c(c1)OCC2)N1CC[C@H](CCCc2ccc3c(n2)NCCC3)C1=O

nearest known ligand 0.82

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 20/20 0.82
ITGAV P06756 20/20 0.82
ITGA2B P08514 4/20 0.48
ITGB1 P05556 1/20 0.48
ITGB6 P18564 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3889422 1.00 ITGB3 (0.82) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL7944308 1.00 ITGB3 (0.82) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL4378963 1.00 ITGB3 (0.82) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL3893571 0.90 ITGB3 (1.00) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL3885035 0.90 ITGB3 (1.00) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL3886509 0.90 ITGB3 (1.00) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL3885043 0.90 ITGB3 (1.00) ITGB3ITGAVITGA2BITGB1ITGB6
SCHEMBL4381844 0.86 ITGAV (0.61) ITGB3ITGAVITGA2BITGB6
SCHEMBL7936743 0.86 ITGAV (0.61) ITGB3ITGAVITGA2BITGB6
SCHEMBL4381840 0.86 ITGAV (0.61) ITGB3ITGAVITGA2BITGB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1047425-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-22 EP claimed
EP-1047425-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-11-02 EP claimed
WO-1999030709-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO claimed
EP-1047425-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-22 EP disclosed
US-6268378-B1 TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. MERCK & CO., INC. 2001-07-31 US disclosed
EP-1047425-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-11-02 EP disclosed
US-6066648-A USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH MERCK & CO., INC. (US) 2000-05-23 US disclosed
WO-1999030709-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO disclosed